BioAssay Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioAssay Sciences is a specialized service provider in the bioassay development and validation niche, serving primarily large biopharma clients. The company's core value proposition is its proprietary platform and methodology, which it claims can reduce assay development time to under 20 days and cut variation by 10-25% compared to other platforms. Its business model is built on consulting services, on-site training, and the deployment of its automated reporting and data handling platform to improve client productivity and regulatory compliance. With a track record of working with Fortune 500 companies globally, it focuses on cost-effectiveness and reducing out-of-specification (OOS) results for its clients.

Diagnostics

Technology Platform

Proprietary software and methodology platform for rapid bioassay development, featuring automated reporting, modern statistical modeling, and performance monitoring to reduce variation and accelerate timelines.

Opportunities

The growing complexity of biologics, cell/gene therapies, and biosimilars drives demand for sophisticated assay expertise.

Increasing regulatory emphasis on data integrity and robust analytical methods creates a persistent need for specialized consulting and platform solutions that ensure compliance and efficiency.

Risk Factors

High dependence on R&D spending from large pharma clients and a narrow market niche create vulnerability to industry downturns.

The business faces competition from both in-house client teams and larger CROs, and its reputation is closely tied to a key individual, Dr.

Thomas A.

Little.

Competitive Landscape

BioAssay Sciences competes in a fragmented niche against the internal assay development teams of pharmaceutical companies, large full-service Contract Research Organizations (CROs), and other specialized boutique consulting firms. Its differentiation hinges on its proprietary platform's promised speed, statistical rigor, and reduction in assay variation.

More companies in Diagnostics & Precision Medicine →More companies in United States →